{"schema_version":"1.0","type":"article","title":"Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.md","lang":"en","date":"2026-09-29","publish_at":"2026-09-29T08:00:00+08:00","updated_at":"2026-09-29","category":"商業分析系列","topic":"商業分析系列","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"Historical Genmab milestones, Formosa's equity settlement and gross-profit-based collaboration, and PharmaEngine's first-half 2026 accounts show how contractual achievements become—or differ from—collectable proceeds.","key_points":[],"facts":[],"sections":["【01｜A US$2 Million Milestone Was Achieved. How Much Reached the Bank?】","【02｜Ending the Collaboration: Releasing US$2.2 Million Is Not Another Cash Receipt】","【03｜Harrow Takes Over: Payment Now Depends on First Sale and Gross Profit】","【04｜The Same US$25 Million Meant Two Different Milestones for Genmab】","【05｜PharmaEngine Recognized US$9.795 Million. Why Is That Not the Same as Cash Collection?】","【06｜From “Will Receive” to “Received”: One Additional Record Changes the Conclusion】","References"],"references":[{"title":"[1] [Eyenovia 2024 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682639/000141057825000743/eyen-20241231x10k.htm"},{"title":"[2] [Hyperion DeFi (formerly Eyenovia) Q2 2025 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682639/000141057825001740/hypd-20250630x10q.htm"},{"title":"[3] [Harrow Form 8-K, June 9, 2025]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm"},{"title":"[4] [Harrow–Formosa joint announcement]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/ex99.htm"},{"title":"[5] [PharmaEngine US$50m milestone announcement, February 5, 2025]","source":"","date":"","url":"https://www.pharmaengine.com/en/investors/investors_5/88"},{"title":"[6] [PharmaEngine ONIVYDE product and milestone history]","source":"","date":"","url":"https://www.pharmaengine.com/en/product/index/8"},{"title":"[7] [PharmaEngine Q2 2026 financial report, page 20]","source":"","date":"","url":"https://www.pharmaengine.com/en/uploads/en/investors_3/20260817374.pdf"},{"title":"[8] [Genmab DARZALEX sales milestone, January 6, 2017]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2017/01/06/904135/0/en/Genmab-Achieves-USD-25-Million-Sales-Milestone-in-DARZALEX-daratumumab-Collaboration-with-Janssen.html"},{"title":"[9] [Genmab first commercial sale in Japan, November 14, 2017]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2017/11/14/1186131/0/en/Genmab-Achieves-USD-25-Million-Milestone-for-First-Commercial-Sale-of-DARZALEX-daratumumab-in-Japan-and-Updates-Financial-Guidance.html"},{"title":"[10] [Genmab–Janssen agreement dated August 30, 2012, filed with the SEC]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zex-10_1.htm"},{"title":"[11] [Formosa announcement of Harrow agreement, June 9, 2025]","source":"","date":"","url":"https://www.formosapharma.com/harrow-acquires-u-s-commercial-rights-to-byqlovi-clobetasol-propionate-ophthalmic-nanosuspension-0-05-from-formosa-pharmaceuticals/"},{"title":"[12] [Formosa Q1 2026 financial report, page 34]","source":"","date":"","url":"https://www.formosapharma.com/wp-content/uploads/2026/06/%E5%8F%B0%E6%96%B0%E8%97%A5.2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%B8%80%E5%AD%A3.FS_.AllReport.ENG_0529.pdf"}],"images":[{"alt":"Three stages: event achieved, notice and invoice, and cash received; alternative contractual triggers appear on the left.","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine-en/01_%E4%BA%8B%E4%BB%B6%E8%AB%8B%E6%AC%BE%E6%94%B6%E7%8F%BE_EN_v1.png"},{"alt":"Four dimensions of a license agreement: resources, achievement, evidence, and rights handover.","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine-en/02_%E5%90%88%E7%B4%84%E6%8E%A7%E5%88%B6%E6%AC%8A_EN_v1.png"},{"alt":"Annual sales of US$500m and first commercial sale in Japan separately trigger US$25m.","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine-en/03_%E6%AD%B7%E5%8F%B2%E8%A7%B8%E7%99%BC%E5%B0%8D%E7%85%A7_EN_v1.png"},{"alt":"Two income categories as of June 30, 2026. US$4.900m is a subset of US$9.795m.","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine-en/04_%E8%AA%8D%E5%88%97%E8%88%87%E6%94%B6%E6%AC%BE_EN_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine-en/01_%E4%BA%8B%E4%BB%B6%E8%AB%8B%E6%AC%BE%E6%94%B6%E7%8F%BE_EN_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-29）。Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash。https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}